Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford...